The increase in α2,6 sialylation of N-glycans is driven by the sialyltransferases ST6GAL1, which is overexpressed in numerous cancer types and are fundamental for tumor growth, metastasis, immune evasion, and drug resistance (27). Here, ST6GAL1 is linked to neoplasm.